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Interleukin-33Background: Soluble ST2 (sST2) is gaining growing interest as a biomarker in heart failure. So far, the ELISA-format is
widely used for commercially available ST2 assays, which hampers their use in clinical routine. Recently, a rapid
quantitative lateral ﬂow immunoassay for the measurement of sST2 in human plasma has been developed.
Methods:Weevaluatedprecision and linearity of theASPECT-PLUS ST2 test, andperformedananalytical and clinical
assay comparison with theMBL and the PRESAGE ST2 ELISAs. Wemeasured sST2with these three assays in a clin-
ical cohort of 251 consecutive patients with acute dyspnea as the chief compliant (i.e., 137 patients with dyspnea
attributable to heart failure and 114 patients with dyspnea attributable to other reasons).
Results:Within-run and total coefﬁcients of variation of the ASPECT-PLUS ST2 testwere b17% and the assaywas lin-
ear across its measurement range. We found a constant and proportional bias between the MBL ST2 assay, the
PRESAGE ST2 assay and the ASPECT-PLUS ST2 test, respectively. However, at the proposed cut-off of 35 ng/mL,
sST2 results obtained with the PRESAGE ST2 assay and the ASPECT-PLUS ST2 test were similar. Testing clinically,
the three assays deemed equally useful for the diagnosis of heart failure (AUC, 0.670 for the MBL ST2 assay vs.
0.626 for the PRESAGE ST2 assay vs. 0.630 for the ASPECT-PLUS ST2 test) and for the prediction of 1-year
mortality in dyspnoeic patients (AUC, 0.743 for the MBL assay vs. 0.742 for the PRESAGE ST2 assay vs. 0.752 for
the ASPECT-PLUS ST2 test).
Conclusion: The ASPECT-PLUS test meets the analytical requirements for point-of-care testing. Test results of the
ASPECT-PLUS ST2 and the PRESAGE ST2 methods were comparable at the proposed cut-off, and the diagnostic/
prognostic capabilities of the three methods were similar.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Soluble ST2 (sST2), an interleukin-1 (IL-1) receptor family member,
is secreted into the circulation and functions as a “decoy” receptor for
interleukin-33 (IL-33), thereby inhibiting IL-33/ST2 signaling [1]. sST2
is currently gaining growing interest as candidate biomarker in heart
failure [1–3]. There is increasing evidence that sST2 plasma concentra-
tions provide prognostic information in patientswith cardiac disease in-
dependently of and additive to other established markers such as
cardiac troponins or natriuretic peptides [4–5]. Thus, sST2 and has
been included in the 2013 ACCF/AHA guideline for additive risk stratiﬁ-
cation of patients with acute and chronic heart failure [6].
So far, the enzyme-linked immunosorbent assay (ELISA) format is
widely used for commercially available ST2 assays, which hampers
their use in clinical routine [5,7]. Recently, the manufacturer of the
PRESAGE ST2 ELISA assay (Critical Diagnostics) has developed they Medicine, Konventhospital
ria.
plinger).
. This is an open access article underASPECT-PLUS ST2 test, a rapid quantitative lateral ﬂow immunoassay
for measurement of sST2 in human plasma.
The aim of this study was to perform (1) an analytical evaluation of
ASPECT-PLUS ST2 test; (2) a method comparison with the MBL ST2
assay (Medical & Biological Laboratories International) and the PRESAGE
ST2 assay; and (3) a comparison of the clinical utility of these three
methods for the diagnosis of heart failure and for the prediction of
death in patients with shortness of breath presenting to an emergency
department.
2. Materials and methods
2.1. Study protocol
This work was performed at St. John of God Hospital in Linz, Austria.
The studyprotocolwas approved by the local ethics committee in accor-
dance with the Declaration of Helsinki, and all study participants gave
informed consent. Blood was obtained by conventional venipuncture
avoiding venous stasis. Using VACUETTE® polyethylene terephthalate
glycol blood collection tubes (Greiner Bio-One), EDTA anticoagulatedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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°Cuntil further analysis. Further speciﬁcations of this analytical and clin-
ical assay evaluation are described in the respective paragraphs of this
methods section.
2.2. sST2 measurements
The ASPECT-PLUS ST2 test is a rapid lateral ﬂow immunoassay for
the quantitative measurement of sST2 in human plasma to be used
with the ASPECT reader. The ASPECT PLUS ST2 test cassette usesmurine
mouse monoclonal antibodies against human sST2, goat polyclonal an-
tibodies against murine IgG, and a ﬂuorescent dye. The ﬂuorescent sig-
nal is measured with the ASPECT reader and the quantitative sST2
values reported are based on a linear calibration curve unique to each
lot and are given as ng/mL.
The measurement of sST2 ASPECT-PLUS ST2 test was performed fol-
lowing the manufacturer's instruction. In brief, after the ASPECT-PLUS
ST2 test cassette was warmed to room temperature for 15 min, the
foil pouch was removed and 35 μl of plasma sample was pipetted into
the sample well; 60 s after loading the plasma sample, 2 drops
(i.e., ~110 μL) of test buffer were added into the test buffer well. Finally,
the ASPECT-PLUS ST2 test cassette was inserted into the ASPECT reader
and the quantitative sST2 results in ng/mL were displayed on the
screen approximately 20 min later. sST2 plasma concentrations less
than 12.5 ng/mL or greater than 250 ng/ml were reported by the
ASPECT Reader as b12.5 ng/ml and N250 ng/mL. Therefore, in the pres-
ent study all values below 12.5 ng/mL are given as 12.5 ng/mL. For this
reason, we were not able to evaluate the limit of detection of the
ASPECT-PLUS ST2 test. According to the information in the package in-
sert the limit of detection is 12.5 ng/mL for the ASPECT-PLUS test.
As prescribed previously by our group, the MBL ST2 ELISA was per-
formed on a BEP 2000 instrument (Siemens Diagnostics) with a
within-run coefﬁcient of variation (CV) of b7.5% and a total CV of
b13% [8]. To our knowledge, there is currently no published data in
the scientiﬁc literature on the detection limit of the MBL ST2 assay. Ac-
cording to the information in the package insert the limit of detection is
0.032 ng/mL for the MBL ST2 assay.
The PRESAGE ST2 ELISA was also measured on a BEP 2000 instru-
ment with a within-run CV of b2.5% and a total CV of b4.0% [9]. For
the PRESAGE ST2 assay there are two previously published studies
that determined the limit of detection of the PRESAGE ST2 assay,
which have reported a limit of the detection of b2.0 ng/mL for the
PRESAGE ST2 assay [9,10]. According to the information in the package
insert the limit of detection is 1.3 ng/mL for the PRESAGE ST2 test.
2.3. Precision study
To evaluate the precision of the ASPECT-PLUS ST2 test in our labora-
tory, we performed a replication study according to the Clinical andTable 1
Data on the analytical assay comparison of the MBL ST2 assay, the PRESAGE ST2 assay and the
sST2 plasma concentrations as measured by the three assays
Assay Lowest value 25th percentile value
MBL ST2 0.189 ng/mL 0.306 ng/mL
PRESAGE ST2 15.4 ng/mL 32.5 ng/mL
ASPECT-PLUS ST2 13.3 ng/mL 31.1 ng/mL
Passing and Bablok regression equitations
Assays compared Regression equitation
MBL (variable x) vs. PRESAGE (variable y) y [ng/mL] = 6.6 ng/mL + 71.
MBL (variable x) vs. ASPECT-PLUS (variable y) y [ng/mL] =−8.0 ng/mL + 1
PRESAGE (variable x) vs. ASPECT-PLUS (variable y) y [ng/mL] =−16.2 ng/mL +
* Plasma samples of 251 patients with acute dyspnoea were measured with all three ST2 assa
within the measurement range of all three assays.Laboratory Standards Institute (CLSI; formerly NCCLS) guideline EP5-A
[11]. Three pooled patient plasma samples were aliquoted into twenty
1.5 mL plastic tubes for each concentration level and frozen at−80 °C.
We analyzed these samples in duplicate in one run per day for
20 days on a single ASPECT reader. Within-run and total analytical im-
precision (CV) was calculated with the CLSI single-run precision evalu-
ation test [11].
2.4. Evaluation of the linearity
We evaluated the linearity of the ASPECT-PLUS ST2 test according to
the CLSI guideline EP6-A [12] using six different analyte concentrations.
Fresh plasma samples were used to prepare a high- and a low-
concentration pool covering the whole measurement range of the
assay. We then conducted a direct dilution series with the low- and
high-concentration patient sample pools in the following volume ratios
(low-concentration pool + high-concentration pool): pool 1, low only;
pool 2, 0.8 low+ 0.2 high; pool 3, 0.6 low+ 0.4 high; pool 4, 0.4 low+
0.6 high; pool 5, 0.2 low + 0.8 high; and pool 6, high only. Three mea-
surements were done on each concentration, and the default criteria
were set at 20% for repeatability and 5 ng/mL for nonlinearity.
2.5. Method comparison
For the method comparison of the MBL ST2, the PRESAGE ST2 and
the ASPECT-PLUS ST2 test, we used plasma samples frozen at−80 °C
from our previously described cohort of 251 consecutive patients at-
tending an emergency department with acute dyspnea as a chief com-
plaint [13–15]. sST2 plasma concentrations were measured with the
MBL ST2 assay from a frozen aliquot as previously described in one
batch in 2007 (approximately three years after blood collection) [14].
sST2 plasma concentrations were measured with the PRESAGE ST2
and the ASPECT-PLUS ST2 assay from another frozen aliquot at the
same time in one batch in August 2015.
For the analytical method comparison, we used the approach of
evaluating plasma concentrations within the measurement ranges of
the three assays only, in order to avoid problems with assay detection
limits in case of very low plasma concentrations or necessary sample di-
lutions in case of plasma concentrations higher than the upper limit of
the measurement range. As a consequence, we had a measurement
range of 0.1875–12 ng/mL for the MBL ST2 assay (based on a 3-fold di-
lution of patient samples), a measurement range of 2.8–180 ng/mL for
the PRESAGE ST2 assay (based on a 45-fold dilution of patient samples),
and a measurement range of 12.5–250 ng/mL for the ASPECT-PLUS ST2
test (based on undiluted patient samples). Of the 251 plasma samples
from our short of breath patients, we were able to use 146 plasma sam-
ples fulﬁlling these requirements for our analytical method comparison.
For the clinical method comparison we used all 251 patient samples
of the entire cohort to compare the diagnostic and prognosticASPECT-PLUS ST2 assay.⁎
Median value 75th percentile value Highest value
0.504 ng/mL 0.796 ng/mL 5.811 ng/mL
45.4 ng/mL 64.8 ng/mL 168.9 ng/mL
48.0 ng/mL 80.3 ng/mL 250.0 ng/mL
Intercept (95% CI) Slope (95% CI)
1 x [ng/mL] 6.6 ng/mL (2.8 to 11.5) 71.1 (61.0 to 81.9)
12.8 x [ng/mL] −8.08 ng/mL (−15.3 to−0.3) 112.8 (97.2 to 132.8)
1.5 x [ng/mL] −16.2 ng/mL (−23.6 to−8.8) 1.5 (1.37 to 1.69)
ys and the data is shown for those 146 plasma samples with sST2 plasma concentrations
Fig. 1. Scatterplots of sST2 plasma concentrations obtained by the three methods in 146
patientswith dyspnea attending an emergency department: (A)MBL ST2 test vs. PRESAGE
ST2 test; (B) MBL ST2 test vs. PRESAGE ST2 test; and (C) PRESAGE ST2 test vs. ASPECT-
PLUS ST2 test.
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heart failure as the cause of dyspnea was based on the Framingham
score for heart failure plus echocardiographic evidence of systolic or di-
astolic dysfunction [13]. The outcomemeasure for the presentworkwas
all-cause mortality at 1 year [15].
2.6. Statistical analysis
For the analytical and clinical comparison of the MBL ST2, PRESAGE
ST2, and ASPECT-PLUS ST2 tests, Passing and Bablok regression and
Spearman's rank correlation analyses were applied. Comparisons of
continuous variables between patient groups were performed with
the non-parametric Mann–Whitney U test. To evaluate the capabilities
of the three sST2 tests for the diagnosis of heart failure and to assess
their capabilities for prediction of all-cause mortality at 1-year we
used receiver operating characteristics (ROC) analyses. In addition,
Kaplan–Meier estimates of the distribution of times from baseline to
death were computed according to median sST2 plasma concentrations
measured with the three different sST2 tests, and log-rank test was per-
formed to compare the survival between the groups. Our data were an-
alyzed with MedCalc 13.0.0.0 (MedCalc Software) and SPSS 13.0 (SPSS
Inc.). Obtained p values were not adjusted for multiple comparisons
and are therefore descriptive only.
3. Results
3.1. Assay evaluation — imprecision and linearity
The ASPECT-PLUS ST2 test had a within-run CV of 16.8% and a total
CV of 17.0% at a mean concentration of 20.8 ng/mL (pool 1), a within-
run CV of 10.1% and a total CV of 10.2% at a mean concentration of
65.6 ng/mL (pool 2), and a within-run CV of 9.6% and a total CV of
10.0% at a mean concentration of 131.8 ng/mL (pool 3).
In the linearity study of the ASPECT-PLUS ST2 test, the low-
concentration pool had a mean sST2 concentration of 23.6 ng/mL
and the high-concentration pool of 229.6 ng/mL. The standard errors
of regression (Sy,x) and t-tests from regression analyses showed that
the ﬁrst-order model ﬁtted better than the second- and third-order
models: ﬁrst-order model b1, Sy,x = 9.5, t-test = 30.8 (p b 0.001);
second-order model b2, Sy,x = 9.6, t-test = 1.0 (p = 0.336); third-
order model b3, Sy,x = 9.7, t-test = 0.82 (p = 0.224). In addition,
all default criteria were met, so the method was linear within its
measurement range.
3.2. Analytical method comparison
The data on 146 patient plasma sampleswith sST2 plasma concentra-
tions within the measurement range of all three assays is shown in
Table 1.
In the 146 dyspnoeic patients, median sST2 plasma concentrations
were 0.504 ng/mL (range, 0.189–5.811 ng/mL; 25th–75th percentiles,
0.306–0.796 ng/mL) as measured by the MBL ST2 assay; 45.4 ng/mL
(range, 15.4–168.9 ng/mL; 25th–75th percentiles, 32.5–64.8 ng/mL)
by the PRESAGE ST2 assay; and 48.0 ng/mL (range, 13.3–250 ng/mL;
25th–75th percentiles, 31.1–80.3 ng/mL) by ASPECT-PLUS ST2 assay.
Non-parametric correlation analyses of the 146 patients revealed a
Spearman's coefﬁcient of rank correlation of 0.829 (95% CI, 0.771–
0.874; p b 0.001) between the MBL ST2 and the PRESAGE ST2, of
0.796 (95% CI, 0.727–0.849; p b 0.001) between the MBL ST2 and the
ASPECT-PLUS ST2, and of 0.892 (0.854–0.921; p b 0.001) between the
PRESAGE ST2 and the ASPECT PLUS ST2 assay.
The comparison of sST2 concentrations obtained with the MBL ST2
(variable x) and the PRESAGE ST2 (variable y) assay in the 146 patients
is shown in Table 1 and Fig. 1A. The following regression equation was
revealed: y = 6.6 (95% CI, 2.8 to 11.5) + 71.1 (95% CI, 61.0 to 81.9) x.
Thus, Passing and Bablok regression suggests in addition to a rathersmall but signiﬁcant constant bias, a high proportional difference be-
tween the two methods. The Cusum test showed no signiﬁcant devia-
tion from linearity (p = 0.37).
Table 2
Clinical comparison of the MBL ST2 assay, the PRESAGE ST2 assay and the ASPECT-PLUS ST2 assay in 251 dyspnoeic patients presenting to the emergency department (n = 251).
Diagnosis: sST2 plasma concentrations according to heart failure classiﬁcation
No heart failure (n = 114) Heart failure (n = 137) p value
MBL ST2, ng/mL 0.202 (0.128–0.500) 0.465 (0.255–0.873) b0.001
PRESAGE ST2, ng/mL 28.5 (19.7–53.5) 40.2 (27.1–68.7) b0.001
ASPECT-PLUS ST2, ng/mL 21.5 (12.5–58.7) 41.2 (22.5–82.0) b0.001
Prognosis: sST2 plasma concentrations according to 1-year all-cause mortality
Survivors (n = 189) Decedents (n = 62) p value
MBL ST2, ng/mL 0.270 (0.147–0.527) 0.755 (0.330–1.794) b0.001
PRESAGE ST2, ng/mL 30.9 (20.4–50.6) 59.3 (34.1–122.5) b0.001
ASPECT-PLUS ST2, ng/mL 25.6 (12.5–52.8) 69.3 (33.4–175.0) b0.001
sST2 plasma concentrations are presented as median (25th–75th percentiles).
Fig. 2. Receiver operating characteristic curves for the biochemical diagnosis of heart fail-
ure by sST2 plasma concentrationsmeasuredwith theMBL ST2 test, the PRESAGE ST2 test,
and the ASPECT-PLUS ST2 test in 251 patients with shortness of breath presenting to the
emergency department (137 patients with dyspnea attributable to heart failure vs. 114
patients with dyspnoea from other causes).
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MBL ST2 (variable x) and the ASPECT-PLUS ST2 (variable y) assay in
the 146patients is displayed in Table 1 and Fig. 1B. The following regres-
sion equationwas revealed: y=−8.0 (95% CI,−15.3 to−0.3)+ 112.8
(95% CI, 97.2 to 132.8) x. Thus, Passing andBablok regression suggests in
addition to a rather small but signiﬁcant constant bias, a high propor-
tional difference between the two methods. The Cusum test showed
no signiﬁcant deviation from linearity (p = 0.37).
Finally, the comparison of sST2 concentrations obtained with the
PRESAGE ST2 (variable x) and the ASPECT-PLUS ST2 (variable y) assay
in the 146 patients is reported in Table 1 and Fig. 1C. The following re-
gression equation was revealed: y =−16.2 (95% CI,−23.6 to−8.8)
+ 1.5 (95% CI, 1.37 to 1.69) x. Thus, Passing and Bablok regression sug-
gests in addition to a considerable constant bias, a considerable propor-
tional difference between the twomethods. The Cusum test showed no
signiﬁcant deviation from linearity (p = 0.76).
3.3. Clinical method comparison — description of the cohort
For the clinical method comparison we used the entire cohort of 251
patients with acute dyspnea presenting to the emergency department
(REF HEART, diagnosis, prognosis, ST2). The median ST2 plasma concen-
trations for the 251 dyspnoeic patients were 0.333 ng/mL (range,
0.036–9.543 ng/mL; 25th–75th percentiles, 0.164–0.729 ng/mL) for the
MBL ST2 assay, 35.3 ng/mL (range, 7.6–1874.7 ng/mL; 25th–75th percen-
tiles, 21.7–60.3 ng/mL) for the PRESAGE ST2 assay, and 34.3 ng/mL
(range, 12.5–2005.8 ng/mL; 25th–75th percentiles, 13.4–72.6 ng/mL)
for the ASPECT-PLUS ST2 assay.
Of these 251 patients, 73 (29%) showed a sST2 plasma concentration
below the measurement range of the MBL ST2 assay
(i.e., b0.189 ng/mL), none below the measurement range of the
PRESAGE ST2 assay (i.e., b2.8 ng/mL), and 57 (23%) below themeasure-
ment range of the ASPECT-PLUS ST2 assay (i.e., b12.5 ng/mL).
In the entire study cohort of 251 dyspnoeic patients, 137 patients
were classiﬁed as having dyspnoea attributable to heart failure, and
114 patients were classiﬁed as having dyspnoea attributable to other
reasons. Furthermore, during the 1-year follow-up 62 patients (25%)
died and 189 (75%) survived. Median sST2 plasma concentrations mea-
sured with the MBL ST2, the PRESAGE ST2 and the ASPECT-PLUS ST2
assay according to patients with heart failure and without heart failure
aswell as according to survivors and decedents are displayed in Table 2.
sST2 plasma concentrationsmeasured with all three assays were signif-
icantly higher in patients with heart failure compared to patients with
dyspnea due to other reasons and also increased in decedents when
compared to survivors (Table 2).
3.4. Clinical method comparison — diagnostic capabilities
In distinguishing between patients with dyspnoea caused by heart
failure (n=137) and patientswith dyspnea attributable to other causes(n=114), the areas under the curve for the three sST2 assayswere sim-
ilar: 0.670 (95% CI, 0.608–0.728) for theMBL ST2; 0.626 (95% CI, 0.563–
0.686) for the PRESAGE ST2; and 0.630 (95% CI, 0.567–0.690) for the
ASPECT-PLUS ST2 assay. Corresponding ROC plots for the diagnosis of
heart failure are displayed in Fig. 2.3.5. Clinical method comparison — prognostic capabilities
The prognostic capabilities of the three different sST2 assays for all-
cause mortality at 1 year in the 251 study participants are visualized by
the ROC curves of Fig. 3. The areas under the curve for the prediction of
deathwere: 0.743 (95% CI, 0.675–0.788) for theMBL ST2; 0.742 (95% CI,
0.683–0.795) for the PRESAGE ST2; and 0.752 (95% CI, 0.694–0.0.804)
for the ASPECT-PLUS ST2 assay.
Fig. 4 shows the Kaplan–Meier curves of the 251 study participants,
who were stratiﬁed into two groups each according to median sST2
plasma concentrations measured with the MBL ST2 assay (i.e.
≥0.333 ng/mL, Fig. 4a), the PRESAGE ST2 assay (i.e. ≥35 ng/mL, Fig.
4B), and the ASPECT-PLUS ST2 test (i.e. ≥34 ng/mL, Fig. 4C), respective-
ly. All-causemortality at 1-yearwas signiﬁcantly higher in patientswith
increased plasma concentrations (logrank test, p b 0.001 for each sST2
test): hazard ratio of 3.73 (95% CI, 2.26–6.15) for the MBL ST2 assay;
hazard ratio of 3.40 (95% CI 2.06–5.60) for the PRESAGE ST2 assay;
and hazard ration of 3.37 (95% CI 2.04–5.55) for the ASPECT-PLUS ST2
test.
Fig. 4. Kaplan–Meier plots showing survival in 251 patients with acute dyspnea stratiﬁed
according tomedian sST2 plasma concentrationsmeasuredwith the (A)MBL ST2 test; the
(B) Presage ST2 test; and (C) the ASPECT-PLUS ST2 test.
Fig. 3. Receiver operating characteristic plots demonstrating the ability of sST2 plasma
concentrations measured with the MBL ST2, the PRESAGE ST2, and the ASPECT-PLUS
ST2 test to predict 1 year all-cause mortality in 251 patients with shortness of breath pre-
senting to the emergency department (62 decedents vs. 189 survivors).
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prognosis of the 137 patients with heart failure (n = 137) as well
(data not shown).
4. Discussion
Our analytical evaluation of the novel ASPECT-PLUS ST2 test, re-
vealed that this rapid lateral ﬂow immunoassay for the quantitative
measurement of sST2 in human plasmameets the quality speciﬁcations
for laboratory medicine considering that this is a point-of-care assay.
The precision study of the ASPECT-PLUS ST2 assay showed that the
within-run and total imprecision CVswere b17%, whichwere adequate,
especially for a point-of-care format assay. Furthermore, we reported
that the assay is linear within its whole measurement range. However,
the limit of detection of the ASPECT-PLUS ST2 assay is 12.5 ng/mL and,
therefore, it has a disadvantage with respect to its low-end sensitivity
compared to the PRESAGE ST2 assay which is considered a “high-sensi-
tivity” assay [9]. Consequently, the ASPECT-PLUS ST2 test is probably
not as suitable for risk stratiﬁcation of healthy and/or population
based cohorts as it has been shown for the PRESAGE ST2 assay [16].
In the present study, we did ﬁnd a considerable constant and propor-
tional bias between the PRESAGE ST2 and the ASPECT-PLUS ST2 assay.
However, at the proposed cut-off value of 35 ng/mL the sST2 results ob-
tained with both methods were very similar. Reasons for the differences
are most probably different assay formats as well as different antibodies
and reagents used for the PRESAGE ST2 and the ASPECT-PLUS ST2 assays.
Furthermore, we conﬁrmed the results of our previous assay comparison
studies on theMBL ST2 and the PRESAGE ST assay [7,17].We found about
100-fold higher median sST2 plasma concentrations using the PRESAGE
ST2 assay compared with the MBL ST2 assay. In addition, we report sim-
ilar differences in median sST2 plasma concentrations obtained with the
MBL ST2 assay and the ASPECT-PLUS ST2 assay.
In this context, the median plasma concentrations of the entire co-
hort of 251 short of breath patients were 0.333 ng/ml for the MBL ST2
assay, 35 ng/mL for the PRESAGE ST2 assay, and 34 ng/mL for the
ASPECT-PLUS ST2 assay. The median we found for the PRESAGE
ST2 assay in our cohort ﬁts perfectly to the proposed cut-off value of
35 ng/ml for risk stratiﬁcation of patients with heart failure.
Another important result of our study is that we found no relevant
differences in the diagnostic and prognostic capabilities of the three
sST2 assays in our clinical cohort of dyspnoeic patients.
As shown in previous reports on this study cohort of dyspnoeic pa-
tients, the diagnostic value of sST2 measured with the MBL ST2 assayfor acute heart failure was only very modest [14]. With the present
study we now further extend this ﬁnding to the PRESAGE ST2 and the
ASPECT-PLUS ST2 assay with similar areas under the curve for the
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and now conﬁrmed, the analyte sST2 lacks disease speciﬁcity [5,7,14]
and is, therefore, not a valuablemarker for the diagnosis of heart failure.
In contrast, we and others have previously shown that sST2 can
serve as a prognostic marker in patients with heart failure and in pa-
tients with dyspnea [8,15,18–20]. Here, we now show for the ﬁrst
time a comparison of the prognostic capability of three different sST2
assays in patients with acute dyspnea. Interestingly, there was no clini-
cal relevant difference in the prognostic performance of one of the three
assays. We saw similar areas under the curve in ROC curve analysis for
the prediction of 1-year all-cause mortality for the MBL, the PRESAGE
and the ASPECT-PLUS ST2 tests. Furthermore, when stratiﬁed according
to median sST2 plasma concentrations we found similar hazard ratios,
with a ~3.5 fold increased risk for patients with ST2 plasma concentra-
tions above the median.
So far, the PRESAGE ST2 assay is the only method that has been
cleared by the U.S. Food and Drug Administration (FDA) and has re-
ceived Conformitѐ Europѐenne (CE) mark. The MBL ST2 assay is a re-
search use only assay. Recently, the ASPECT-PLUS ST2 test and the
ASPECT reader have received CE mark. However, FDA clearance is still
due for the ASPECT-PLUS ST2 test.
Another important point for implementation of sST2 testing in clin-
ical routine is laboratory costs. When taking into account the reagent
price only for sST2 measurement with the three different assays
(i.e., excluding costs for staff and equipment), the costs for a single
sST2 measurement are roughly 6 € for the MBL ST2 test, 10 € for the
PRESAGE ST2 test, and 20 € for ASPECT-PLUS ST2 test. However, one
has to keep in mind the different assay formats (ELISA-format for the
MBL ST2 and the PRESAGE ST2 test and point of care testing-format of
the ASPECT-PLUS ST2 test) with different hands-on and turn-around
times.
In conclusion, the ASPECT-PLUS assay meets the analytical require-
ments for point-of-care testing. An advantage of the ASPECT-PLUS ST2
test is the point-of-care format with low hands on time and the fast
turn-around time, whichmakes timely and single samplemeasurements
sST2 feasible. Even though, there was a considerable constant and pro-
portional bias between the ASPECT-PLUS ST2 and the PRESAGE ST2
assay, we obtained similar results at the proposed cut-off of 35 ng/mL
with both methods. Importantly, we found no relevant difference with
respect to the diagnostic and prognostic capabilities of the ASPECT-
PLUS ST2 and the PRESAGE ST2 in acute dyspnoeic patients attending
an emergency department.
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